renal cell cancerelderly patientssorafenibquality of lifeпочечно-клеточный ракбольные старческого возрастасорафенибкачество жизни1.1. Ahmad T., Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10(18): 6388—92.Ahmad T., Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10(18): 6388—92.2.2. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125—34 .Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125—34 .3.3. Therasse P., Arbuck S.G., Eisenhauer E.A. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205—16.Therasse P., Arbuck S.G., Eisenhauer E.A. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205—16.4.4. Cella D.F., Yount S., Du H. et al. Development and validation of the Functional Assessment of Cancer Therapy- Kidney Symptom Index (FKSI). J Support Oncol 2006;4(4):191—9.Cella D.F., Yount S., Du H. et al. Development and validation of the Functional Assessment of Cancer Therapy- Kidney Symptom Index (FKSI). J Support Oncol 2006;4(4):191—9.5.5. Cella D.F., Tulsky D.S., Gray G. et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11(3):570—9.Cella D.F., Tulsky D.S., Gray G. et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11(3):570—9.6.6. Wilhelm S.M., Carter C., Tang L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progres- sion and angiogenesis. Cancer Res 2004;64(19):7099—109.Wilhelm S.M., Carter C., Tang L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progres- sion and angiogenesis. Cancer Res 2004;64(19):7099—109.7.7. Pili R., Guo Y., Chang J. et al. Altered angiogenesis underlying age-dependent changes in tumor growth . J Natl Cancer Inst 1994;86(17):1303—14.Pili R., Guo Y., Chang J. et al. Altered angiogenesis underlying age-dependent changes in tumor growth . J Natl Cancer Inst 1994;86(17):1303—14.8.8. Kaptzan T., Skutelsky E., Itzhaki O. et al. Effi cacy of anti-angiogenic treatment of tumors in old versus young mice . Mech Ageing Dev 2006;127(4):398—409.Kaptzan T., Skutelsky E., Itzhaki O. et al. Effi cacy of anti-angiogenic treatment of tumors in old versus young mice . Mech Ageing Dev 2006;127(4):398—409.9.9. Atzpodien J., Wandert T., Reitz M. Age does not impair the effi cacy of immunochemotherapy in patients with metastatic renal carcinoma. Crit Rev Oncol Hematol 2005;55(3):193—9.Atzpodien J., Wandert T., Reitz M. Age does not impair the effi cacy of immunochemotherapy in patients with metastatic renal carcinoma. Crit Rev Oncol Hematol 2005;55(3):193—9.10.10. Schoffski P., Dumez H, Clement P. et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell can- cer: a review. Ann Oncol 2006;17(8): 1185—96.Schoffski P., Dumez H, Clement P. et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell can- cer: a review. Ann Oncol 2006;17(8): 1185—96.